[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dongying Zhang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100578534","phase-4-efficacy-and-safety-of-early-initiation-of-vericiguat-in-heart-failure-after-acute-myocardial-infarction-100578534",false,"NCT06812546","Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction","VIC-MI","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Undertaking revascularization for criminal coronary artery during hospitalization\n* Acute heart failure occurs within 14 days in hospital after STEMI or NSTEMI, meeting all of the following criteria: typical symptoms or signs of heart failure; Treatment with oral or intravenous diuretics is required; LVEF measured by echocardiography is ≤ 45%; Elevated levels of NT proBNP in patients with sinus rhythm ≥ 1000pg\u002Fml and atrial fibrillation\u002Fflutter ≥ 1600pg\u002Fml\n* eGFR ≥ 15 ml\u002Fmin\u002F1.73m2\n* Informed consent has to be given in written form\n\nExclusion Criteria:\n\n* Plan to undergo staged revascularization or if the criminal coronary artery has not been successfully opened\n* Severe and uncontrolled lung diseases, such as newly developed pulmonary embolism, primary pulmonary hypertension, acute exacerbation of COPD, etc\n* Severe liver and kidney dysfunction, Child Pugh grade C or eGFR \\\u003C 15ml\u002Fmin\u002F1.73m2\n* Allergies to ACEI, ARB, ARNI, beta blockers, SGLT2i, MRA, Vericiguat, and other medications\n* Symptomatic hypotension or systolic blood pressure less than 90mmHg after discontinuing intravenous medication\n* Women in the perinatal period or those planning to conceive\n* Patients planning to undergo elective surgical treatment or tumor chemotherapy\n* Diagnosed as Takotsubo cardiomyopathy or nonobstructive acute myocardial infarction (MINOCA)\n* Previous diagnosis of cardiomyopathy, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, etc.\n* Autoimmune disease or infectious diseases with typical cardiovascular damage, such as syphilis, systemic lupus erythematosus, etc.\n* Diagnosed with severe heart valve disease","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Heart failure (HF) is a severe cardiovascular disease with extremely high morbidity and mortality rates worldwide, and ischemic cardiomyopathy is an important cause of heart failure. Vericiguat is a soluble guanylate cyclase stimulator which has been verified to improve the cardiovascular outcomes in heart failure patients. The VICTORIA trial excluded patients with acute coronary syndrome in 3 months prior to the study start, so it is still unclear about the efficacy and safety of vericiguat in heart failure after acute myocardial infarction. So we conducted this multi-center, prospective, cohort study to estimate the efficacy and safety of vericiguat in HF patients after acute myocardial infarction.",[26,27,28],"Heart Failure","Acute Myocardial Infarction (AMI)","Acute Heart Failure (AHF)",[30,31,26,32],"Vericiguat","Guideline-Directed Medical Therapy","Acute myocardial infarction","NOT_YET_RECRUITING","2025-02-02",{"date":36,"type":37},"2025-02-06","ACTUAL",{"date":39,"type":20},"2025-04-01",{"date":41,"type":20},"2026-12-30",{"name":43,"class":44},"Dongying Zhang","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100562549","phase-4-colchicine-in-patients-with-heart-failure-with-preserved-ejection-fraction-and-inflammation-100562549","NCT06604611","Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation","Efficacy and Safety of Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation","CHIPS","Inclusion Criteria:\n\n* Left ventricular ejection fraction measured by echocardiography ≥ 50%\n* Objective evidence of structural of functional abnormalities measured by echocardiography: 1)LVMI≥95 g\u002Fm2 in female and ≥115 g\u002Fm2 in male or 2)LAVI greater than 29ml\u002Fm2 in sinus rhythm or greater than 40ml\u002Fm2 in atrial fibrillation or 3)Average E\u002Fe' greater than 14 or 4)TR velocity greater than 2.8 m\u002Fs\n* Patients with elevated NT-proBNP levels 24 hours after discontinuing intravenous diuretics: ≥300 pg\u002Fml in patients with sinus heart rate; ≥600 pg\u002Fml in patients with atrial fibrillation\n* Both outpatient and admitted patients can be considered for enrollment. All patients must occurred worsening heart failure event within 30 days prior to randomization and a current NYHA cardiac function class II-IV\n* Patients with CRP levels greater than 2mg\u002FL\n* Patient agrees to join and signs a written informed consent form\n\nExclusion Criteria:\n\n* Received colchicine treatment within one month prior to randomization\n* Acute coronary syndrome within 3 months prior to randomization, or history of pacemaker implantation, PCI, CABG within 3 months\n* eGFR less than 25 mL\u002Fmin\u002F1.73 m2\n* Liver function Child-Pugh class B or C\n* Patient has a history of previous allergy to colchicine or dapagliflozin \u002F empagliflozin\n* Heart failure due to the following reasons: pericardial disease, pericardial effusion, myocarditis, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and other rare cardiomyopathies such as Fabry disease\n* Combined diagnosis of gastric ulcer, ulcerative colitis, Crohn disease and other digestive disorders or combined gastrointestinal tumors\n* Plan to undergo cardiac surgery such as coronary revascularization, radiofrequency ablation of arrhythmias, valve replacement or other surgical procedures\n* Pregnant or breastfeeding women\n* The patient who is cognitively impaired and is unable to accurately complete the assessment and completion of the KCCQ scale with the assistance of a physician\n* Autoimmune diseases such as systemic lupus erythematosus, long-term adrenocorticotropic hormone treatment for other diseases such as Schihan syndrome, or need to accept immunosuppressive drugs and monoclonal antibodies such as IL-1 and IL-6\n* Patient with combined active solid tumor or hematological malignancy\n* Patient comorbidity with other conditions that may be confused with HFpEF symptoms, such as acute exacerbation of COPD\n* Admission with a well-defined infection (symptoms or pathogenetic evidence of infection, and leukocytes greater than 10\\*109\u002FL)\n* Previously diagnosed with HFrEF (initial assessment of LVEF less than 40%) or diagnosed with LVimpEF",{"count":19,"type":20},[23],"The main purpose of the CHIPS trial is to evaluate the efficacy and safety of colchicine in heart failure with preserved ejection fraction (HFpEF) patients with inflammation, including the effects of colchicine on circulating inflammatory markers, cardiac structure, cardiac function, clinical symptoms and exercise capacity in HFpEF patients.",[26,58,59,60,61],"Heart Failure With Preserved Ejection Fraction (HFPEF)","Chronic Inflammation","Inflammation","Colchicine",[26,63,60],"Heart Failure with Preserved Ejection Fraction (HFpEF)","2024-09-17",{"date":66,"type":37},"2024-09-19",{"date":68,"type":20},"2024-10-31",{"date":70,"type":20},"2026-03-31",{"name":43,"class":44},""]